Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Department of Pharmacy, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, 110042, China.
Trends Cancer. 2020 Aug;6(8):645-659. doi: 10.1016/j.trecan.2020.05.001. Epub 2020 May 21.
Tumor metastases, that is, the development of secondary tumors in organs distant from the primary tumor, and their treatment remain a serious problem in cancer therapy. The unique challenges for tracking and treating tumor metastases lie in the small size, high heterogeneity, and wide dispersion to distant organs of metastases. Recently, nanomedicines, with the capacity to precisely deliver therapeutic agents to both primary and secondary tumors, have demonstrated many potential benefits for metastatic cancer theranostics. Given the remarkable progression in emerging nanotherapeutics for antimetastatic treatment, it is timely to summarize the latest advances in this field. This review highlights the rationale, advantages, and challenges for integrating biomedical nanotechnology with cancer biology to develop antimetastatic nanotherapeutics.
肿瘤转移，即原发肿瘤远处器官的继发性肿瘤的发展，以及它们的治疗仍然是癌症治疗中的一个严重问题。跟踪和治疗肿瘤转移的独特挑战在于转移的小尺寸、高异质性和广泛分散到远处器官。最近，纳米医学能够将治疗剂精确地递送到原发和继发肿瘤，为转移性癌症的治疗诊断提供了许多潜在的好处。鉴于新兴的抗转移治疗纳米疗法的显著进展，及时总结该领域的最新进展是适时的。本综述强调了将生物医学纳米技术与癌症生物学相结合开发抗转移纳米疗法的原理、优势和挑战。
